Kura Oncology Inc. (KURA) Downgraded by Zacks Investment Research
Kura Oncology Inc. (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Oppenheimer Holdings Inc. reissued an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Sunday, August 14th.
Kura Oncology (NASDAQ:KURA) opened at 6.20 on Tuesday. The company has a 50-day moving average of $6.02 and a 200 day moving average of $4.10. The company’s market cap is $116.21 million. Kura Oncology has a 52-week low of $2.50 and a 52-week high of $25.00.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Equities research analysts predict that Kura Oncology will post ($1.58) EPS for the current year.
A hedge fund recently bought a new stake in Kura Oncology stock. Minerva Advisors LLC acquired a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned 1.96% of Kura Oncology at the end of the most recent reporting period. Institutional investors own 43.63% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.